Roche said profit climbed in 2016, as several of its top-selling drugs continued to prosper in the absence of cheaper competitors, while its chief executive shrugged off Donald Trump’s criticism of high drug prices.
from WSJ.com: US Business http://ift.tt/2kr361T
via IFTTT
No comments:
Post a Comment